Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Performance

Consolidated results for the third quarter of the fiscal year ending March 2026 recorded net sales of JPY 22,803 million (11.0% YoY increase), operating income of JPY 2,623 million (28.5% YoY increase), ordinary income of JPY 2,710 million (28.0% YoY increase), and net income attributable to owners of the parent for the quarter of JPY 1,760 million (24.2% YoY increase). By segment, the DX & SI business recorded net sales of JPY 14,518 million (14.0% YoY increase) and operating income of JPY 2,530 million (10.4% YoY increase); the Package business recorded net sales of JPY 4,727 million (20.2% YoY increase) and operating income of JPY 1,478 million (56.0% YoY increase); and the Medical Big Data business showed solid performance with net sales of JPY 2,033 million (9.0% YoY increase) and operating income of JPY 394 million (66.4% YoY increase). In contrast, the Global business recorded net sales of JPY 1,523 million (24.5% YoY decrease) and an operating loss of JPY 296 million.

Financial Position and Outlook

Total assets slightly decreased to JPY 22,484 million compared to the previous year same period, but net assets increased to JPY 15,586 million, improving the equity ratio to 69.0%. Cash flow from operating activities increased to JPY 3,018 million compared to the previous year same period. Cash outflows from investing activities decreased to JPY 111 million, and cash outflows from financing activities amounted to JPY 1,037 million. The full-year earnings guidance for the fiscal year ending March 2026 remains unchanged, with projected net sales of JPY 32,000 million, operating income of JPY 3,590 million, ordinary income of JPY 3,660 million, and net income attributable to owners of the parent of JPY 2,770 million.